2. Academic Validation
  3. APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells

APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells

  • Br J Cancer. 2024 Jan;130(1):151-162. doi: 10.1038/s41416-023-02484-8.
Mingjue Chen # 1 2,  Tetsuo Mashima # 1,  Taichi Oishi # 1 2,  Yukiko Muramatsu 1,  Yosuke Seto 3,  Manabu Takamatsu 4,  Naomi Kawata 1 5,  Shun Morino 1 2,  Ayane Nakamura 1 6,  Saori Inaba 1,  Xunmei Yuan 1,  Kohei Maruyama 2 3,  Mai Suzuki 2 3,  Ayana Sato 1 2,  Haruka Yoshida 1,  Myung-Kyu Jang 1 2,  Anna Mizutani 1,  Kengo Takeuchi 4,  Kensei Yamaguchi 5,  Fumiyuki Shirai 7,  Satoshi Nagayama 8 9,  Ryohei Katayama 2 3,  Hiroyuki Seimiya 10 11 12
Affiliations

Affiliations

  • 1 Division of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan.
  • 2 Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
  • 3 Division of Experimental Chemotherapy, Cancer Chemotherapy Center, JFCR, Tokyo, Japan.
  • 4 Division of Pathology, The Cancer Institute, JFCR, Tokyo, Japan.
  • 5 Gastroenterological Chemotherapy, Cancer Institute Hospital, JFCR, Tokyo, Japan.
  • 6 Graduate School of Pharmaceutical Sciences, Meiji Pharmaceutical University, Tokyo, Japan.
  • 7 Drug Discovery Chemistry Platform Unit, RIKEN Center for Sustainable Resource Science, Saitama, Japan.
  • 8 Gastroenterological Surgery, Cancer Institute Hospital, JFCR, Tokyo, Japan.
  • 9 Department of Surgery, Uji-Tokushukai Medical Center, Kyoto, Japan.
  • 10 Division of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan. [email protected].
  • 11 Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. [email protected].
  • 12 Graduate School of Pharmaceutical Sciences, Meiji Pharmaceutical University, Tokyo, Japan. [email protected].
  • # Contributed equally.
PMID: 37968472 DOI: 10.1038/s41416-023-02484-8
Abstract

Background: Aberrant Wnt/β-catenin signaling drives carcinogenesis. Tankyrases poly(ADP-ribosyl)ate and destabilize AXINs, β-catenin repressors. Tankyrase inhibitors block Wnt/β-catenin signaling and colorectal Cancer (CRC) growth. We previously reported that 'short' APC mutations, lacking all seven β-catenin-binding 20-amino acid repeats (20-AARs), are potential predictive biomarkers for CRC cell sensitivity to tankyrase inhibitors. Meanwhile, 'Long' APC mutations, which possess more than one 20-AAR, do not predict inhibitor-resistant cells. Thus, additional biomarkers are needed to precisely predict the inhibitor sensitivity.

Methods: Using 47 CRC patient-derived cells (PDCs), we examined correlations between the sensitivity to tankyrase inhibitors (G007-LK and RK-582), driver mutations, and the expressions of signaling factors. NOD.CB17-Prkdcscid/J and BALB/c-nu/nu xenograft mice were treated with RK-582.

Results: Short APC mutant CRC cells exhibited high/intermediate sensitivities to tankyrase inhibitors in vitro and in vivo. Active β-catenin levels correlated with inhibitor sensitivity in both short and long APC mutant PDCs. PIK3CA mutations, but not KRAS/BRAF mutations, were more frequent in inhibitor-resistant PDCs. Some wild-type APC PDCs showed inhibitor sensitivity in a β-catenin-independent manner.

Conclusions: APC/PIK3CA mutations and β-catenin predict the sensitivity of APC-mutated CRC PDCs to tankyrase inhibitors. These observations may help inform the strategy of patient selection in future clinical trials of tankyrase inhibitors.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-137849
    98.05%, Tankyrase Inhibitor